Please enable JavaScript to continue using this application.

Compare $CATX vs $VNDA | Chartloom

Compare

$CATX vs $VNDA

Perspective Therapeutics Inc · Vanda Pharmaceuticals Inc

CATX

Perspective Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Compare $CATX vs $VNDA

Comparing Perspective Therapeutics Inc and Vanda Pharmaceuticals Inc

CATXPerspective Therapeutics Inc

VNDAVanda Pharmaceuticals Inc

CATXPerspective Therapeutics Inc

Market cap

$303M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-66.9%

YTD performance

-4.7%

52W performance

-31.1%

FCF yield

-40.0%

VNDAVanda Pharmaceuticals Inc

Market cap

$275M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.89x

Rev growth (TTM)

6.0%

YTD performance

-44.6%

52W performance

-16.3%

FCF yield

-55.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CATX

VNDA

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Market Cap

CATX$303M

VNDA$275M

Enterprise Value

CATX$256M

VNDA$226M

Price

CATX$2.66

VNDA$4.57

P/E Ratio

CATXN/A

VNDAN/A

P/S Ratio

CATX741.74x

VNDA1.27x

EV/Sales

CATX627.10x

VNDA1.05x

EV/EBITDA

CATX0.00x

VNDA183.49x

P/B Ratio

CATX0.97x

VNDA1.29x

P/FCF Ratio

CATXN/A

VNDAN/A

EV/FCF

CATX-2.11x

VNDA-1.48x

PEG Ratio

CATXN/A

VNDAN/A

Forward P/E (NTM)

CATXN/A

VNDAN/A

Forward P/S (NTM)

CATXN/A

VNDA0.89x

Revenue (TTM)

CATX$409K

VNDA$216M

Revenue Growth (YoY)

CATX-66.9%

VNDA6.0%

Forward Rev Growth

CATX32.5%

VNDA35.6%

Gross Margin (TTM)

CATX23.0%

VNDA93.7%

Operating Margin (TTM)

CATX0.0%

VNDA0.0%

EBITDA Margin (TTM)

CATX-29628.1%

VNDA-82.1%

Net Margin (TTM)

CATX-28468.0%

VNDA-127.4%

FCF Margin (TTM)

CATX-29657.2%

VNDA-70.9%

Net Income (TTM)

CATX$-116M

VNDA$-275M

FCF (TTM)

CATX$-121M

VNDA$-153M

EPS (TTM)

CATX-$0.97

VNDA-$4.56

ROE (TTM)

CATX-4156.0%

VNDA-8495.0%

ROA (TTM)

CATX-3413.0%

VNDA-5679.0%

ROIC (TTM)

CATX-4132.0%

VNDA-8320.0%

Cash

CATX$48M

VNDA$56M

Debt

CATX$2M

VNDA$7M

Net Cash/Debt

CATX$47M

VNDA$49M

Current Ratio (TTM)

CATX6.61x

VNDA1.61x

Quick Ratio (TTM)

CATX6.49x

VNDA1.40x

Debt/Equity (TTM)

CATX0.00x

VNDA0.03x

Debt/Assets (TTM)

CATX0.0%

VNDA0.0%

Interest Coverage (TTM)

CATXN/A

VNDAN/A

Net Debt/EBITDA (TTM)

CATX0.00x

VNDA0.00x

Beta

CATX1.87

VNDA0.69

52W Performance

CATX-31.1%

VNDA-16.3%

YTD Performance

CATX-4.7%

VNDA-44.6%

% from 52W High

CATX-56.8%

VNDA-54.0%

% from 52W Low

CATX35.7%

VNDA7.0%

Asset Turnover (TTM)

CATX0.00x

VNDA0.45x

FCF Yield (TTM)

CATX-40.0%

VNDA-55.7%

Earnings Yield (TTM)

CATX-38.4%

VNDA-100.0%

Dividend Yield (TTM)

CATXN/A

VNDAN/A

Rule of 40

CATX-29,724.1

VNDA-64.9

EV/GP/RG

CATX22.31

VNDA0.01

Ticker research

View CATX research View VNDA research

Metric	CATX Perspective Therapeutics Inc	VNDA Vanda Pharmaceuticals Inc
Market & Valuation
Market Cap	$303M	$275M
Enterprise Value	$256M	$226M
Price	$2.66	$4.57
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	1.27x
EV/Sales	627.10x	1.05x
EV/EBITDA	0.00x	183.49x
P/B Ratio	0.97x	1.29x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-1.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.89x
Revenue & Growth
Revenue (TTM)	$409K	$216M
Revenue Growth (YoY)	-66.9%	6.0%
Forward Rev Growth	32.5%	35.6%
Profitability
Gross Margin (TTM)	23.0%	93.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	-82.1%
Net Margin (TTM)	-28468.0%	-127.4%
FCF Margin (TTM)	-29657.2%	-70.9%
Net Income (TTM)	$-116M	$-275M
FCF (TTM)	$-121M	$-153M
EPS (TTM)	-$0.97	-$4.56
ROE (TTM)	-4156.0%	-8495.0%
ROA (TTM)	-3413.0%	-5679.0%
ROIC (TTM)	-4132.0%	-8320.0%
Financial Health
Cash	$48M	$56M
Debt	$2M	$7M
Net Cash/Debt	$47M	$49M
Current Ratio (TTM)	6.61x	1.61x
Quick Ratio (TTM)	6.49x	1.40x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.69
52W Performance	-31.1%	-16.3%
YTD Performance	-4.7%	-44.6%
% from 52W High	-56.8%	-54.0%
% from 52W Low	35.7%	7.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.45x
FCF Yield (TTM)	-40.0%	-55.7%
Earnings Yield (TTM)	-38.4%	-100.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	-64.9
EV/GP/RG	22.31	0.01
Ticker research	View CATX research	View VNDA research

Valuation

P/S Ratio

VNDA

1.27x

CATX

741.74x

EV/FCF

CATX

-2.11x

VNDA

-1.48x

Growth & revenue

Revenue Growth TTM

VNDA

6.0%

CATX

-66.9%

Forward Revenue Growth

VNDA

35.6%

CATX

32.5%

Profitability & performance

Gross Margin

VNDA

93.7%

CATX

23.0%

ROE

CATX

-4156.0%

VNDA

-8495.0%

FCF Yield %

CATX

-40.0%

VNDA

-55.7%

52-Week Performance

VNDA

-16.3%

CATX

-31.1%

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Market Cap

CATX$303M

VNDA$275M

Enterprise Value

CATX$256M

VNDA$226M

Price

CATX$2.66

VNDA$4.57

P/E Ratio

CATXN/A

VNDAN/A

P/S Ratio

CATX741.74x

VNDA1.27x

EV/Sales

CATX627.10x

VNDA1.05x

EV/EBITDA

CATX0.00x

VNDA183.49x

P/B Ratio

CATX0.97x

VNDA1.29x

P/FCF Ratio

CATXN/A

VNDAN/A

EV/FCF

CATX-2.11x

VNDA-1.48x

PEG Ratio

CATXN/A

VNDAN/A

Forward P/E (NTM)

CATXN/A

VNDAN/A

Forward P/S (NTM)

CATXN/A

VNDA0.89x

Revenue (TTM)

CATX$409K

VNDA$216M

Revenue Growth (YoY)

CATX-66.9%

VNDA6.0%

Forward Rev Growth

CATX32.5%

VNDA35.6%

Gross Margin (TTM)

CATX23.0%

VNDA93.7%

Operating Margin (TTM)

CATX0.0%

VNDA0.0%

EBITDA Margin (TTM)

CATX-29628.1%

VNDA-82.1%

Net Margin (TTM)

CATX-28468.0%

VNDA-127.4%

FCF Margin (TTM)

CATX-29657.2%

VNDA-70.9%

Net Income (TTM)

CATX$-116M

VNDA$-275M

FCF (TTM)

CATX$-121M

VNDA$-153M

EPS (TTM)

CATX-$0.97

VNDA-$4.56

ROE (TTM)

CATX-4156.0%

VNDA-8495.0%

ROA (TTM)

CATX-3413.0%

VNDA-5679.0%

ROIC (TTM)

CATX-4132.0%

VNDA-8320.0%

Cash

CATX$48M

VNDA$56M

Debt

CATX$2M

VNDA$7M

Net Cash/Debt

CATX$47M

VNDA$49M

Current Ratio (TTM)

CATX6.61x

VNDA1.61x

Quick Ratio (TTM)

CATX6.49x

VNDA1.40x

Debt/Equity (TTM)

CATX0.00x

VNDA0.03x

Debt/Assets (TTM)

CATX0.0%

VNDA0.0%

Interest Coverage (TTM)

CATXN/A

VNDAN/A

Net Debt/EBITDA (TTM)

CATX0.00x

VNDA0.00x

Beta

CATX1.87

VNDA0.69

52W Performance

CATX-31.1%

VNDA-16.3%

YTD Performance

CATX-4.7%

VNDA-44.6%

% from 52W High

CATX-56.8%

VNDA-54.0%

% from 52W Low

CATX35.7%

VNDA7.0%

Asset Turnover (TTM)

CATX0.00x

VNDA0.45x

FCF Yield (TTM)

CATX-40.0%

VNDA-55.7%

Earnings Yield (TTM)

CATX-38.4%

VNDA-100.0%

Dividend Yield (TTM)

CATXN/A

VNDAN/A

Rule of 40

CATX-29,724.1

VNDA-64.9

EV/GP/RG

CATX22.31

VNDA0.01

Ticker research

View CATX research View VNDA research

Metric	CATX Perspective Therapeutics Inc	VNDA Vanda Pharmaceuticals Inc
Market & Valuation
Market Cap	$303M	$275M
Enterprise Value	$256M	$226M
Price	$2.66	$4.57
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	1.27x
EV/Sales	627.10x	1.05x
EV/EBITDA	0.00x	183.49x
P/B Ratio	0.97x	1.29x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-1.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.89x
Revenue & Growth
Revenue (TTM)	$409K	$216M
Revenue Growth (YoY)	-66.9%	6.0%
Forward Rev Growth	32.5%	35.6%
Profitability
Gross Margin (TTM)	23.0%	93.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	-82.1%
Net Margin (TTM)	-28468.0%	-127.4%
FCF Margin (TTM)	-29657.2%	-70.9%
Net Income (TTM)	$-116M	$-275M
FCF (TTM)	$-121M	$-153M
EPS (TTM)	-$0.97	-$4.56
ROE (TTM)	-4156.0%	-8495.0%
ROA (TTM)	-3413.0%	-5679.0%
ROIC (TTM)	-4132.0%	-8320.0%
Financial Health
Cash	$48M	$56M
Debt	$2M	$7M
Net Cash/Debt	$47M	$49M
Current Ratio (TTM)	6.61x	1.61x
Quick Ratio (TTM)	6.49x	1.40x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.69
52W Performance	-31.1%	-16.3%
YTD Performance	-4.7%	-44.6%
% from 52W High	-56.8%	-54.0%
% from 52W Low	35.7%	7.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.45x
FCF Yield (TTM)	-40.0%	-55.7%
Earnings Yield (TTM)	-38.4%	-100.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	-64.9
EV/GP/RG	22.31	0.01
Ticker research	View CATX research	View VNDA research